ChronicleBio, a techbio startup focused on accelerating insights on neuroimmune disorders, has launched to build the world’s richest, AI-ready data platform for historically overlooked conditions like POTS, ME/CFS, Long COVID, and other complex chronic conditions.
ChronicleBio led by a founding team consisting of Fidji Simo (co-founder), Rohit Gupta (co-founder and CEO), and Rishi Reddy (co-founder and executive chairman).
ChronicleBio said it is creating a scalable, ethically driven data ecosystem, integrating clinical, molecular, biospecimen, and patient-reported insights to drive biomarker discovery, patient stratification, and precision therapeutic development.
“Entire communities of patients have been ignored for too long, not because their conditions aren’t debilitating and prevalent, but because the systems weren’t built to understand them,” Simo said.
“ChronicleBio is developing a future where patients can enlist in research, and where the data we collect from them goes directly towards better diagnostics and therapeutics. By building these critical missing datasets and leveraging the massive advances in AI, we aim to accelerate the path to cures.”
These complex chronic conditions impact nearly 300m people worldwide, but remain understudied, leaving patients without meaningful treatments.
“Neuroimmune disorders remain some of the most poorly understood in medicine and not for lack of interest, but because the underlying data simply doesn’t exist at the scale or structure required for serious breakthroughs,” Gupta said.
“We’re empowering patients and clinicians to get involved in this effort to grow our research-grade biobank and AI-ready data platform so we can close that gap and provide the tools to finally interrogate these diseases with scientific rigor and precision, bringing an end to complex chronic conditions.”
ChronicleBio partners directly with patients, clinics, and research collaborators to generate longitudinal, multi-modal datasets, including genomics, immune profiling, and real-world outcomes designed for exploration and clinical trial readiness. Its platform is already being used in multiple high-integrity clinics in the US and India, as well as through research collaborations with thousands of patients contributing data and biosamples.
“We’re creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale. The opportunity for impact—scientifically, medically, and societally—is enormous,” Reddy said.
“We’re building the foundational infrastructure for a massive medical need that has been hiding in plain sight.”
ChronicleBio’s approach includes: a global biobank platform collecting and connecting data on neuroimmune illnesses; a proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence; a strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas; and a decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
